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RESUMEN
La inducción y la inhibición de los enzimas dependientes del citocromo P-450
(CYP) son fenómenos biológicos interesantes, de tal manera, que su estudio es muy im-
portante en los ensayos de toxicidad de los agentes químicos, incluyendo los medica-
mentos, y en la terapéutica relacionada con las interacciones de fármacos. Esta revisión
representa una visión breve y sistemática de la inducción y la inhibición, que comien-
za con la recopilación de sustratos típicos y reacciones, los cuales pueden ser utilizados
in vitro para estudiar la actividad de isoenzimas del citocromo P-450 en animales y hu-
manos. La inducción puede caracterizarse desde varios puntos de vista: descripción y
clasificación en base a inductores, enzimas y receptores nucleares. Se presentan los in-
hibidores selectivos del CYP junto con los mecanismos de inhibición, y finalmente se
discuten brevemente interacciones debidas a inhibición con significación clínica. Esta
revisión finaliza con un esbozo de cómo estudiar la inducción y la inhibición durante
el descubrimiento y desarrollo de un nuevo fármaco. 
1. ABSTRACT
Induction and inhibition of cytochrome P-450 (CYP) enzymes is an
interesting biological phenomenon as such, but it is of utmost importan-
ce in toxicity testing of chemicals, including pharmaceuticals, and in drug
therapy presenting as drug-drug interactions. This review represents a
short and systematic view of induction and inhibition, starting with com-
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pilation of typical substrates and reactions, which can be used in in vitro
studies to study activities of cytochrome P-450 enzymes in animals and
humans. Induction is then characterized from various viewpoints: des-
cription and classification of induction on the basis of inducers, enzymes,
and nuclear receptors. CYP-selective inhibitors are then presented, toge-
ther with mechanisms of inhibition and finally some well-characterized
clinically significant inhibitory interactions are briefly discussed. This re-
view ends with an outline how to study induction and inhibition during
drug discovery and development.
2. INTRODUCTION
Detailed knowledge of metabolism of drugs is important, because
1) metabolism determines, to a large extent, pharmacokinetic beha-
viour, interindividual variability and interactions of a drug, all matters
of great importance in drug treatment, and 2) differences in metabo-
lism are also often behind the difficulties in the extrapolation from ani-
mals to humans, which is a serious obstacle in drug testing and deve-
lopment. Factors affecting drug metabolism are usually classified into
genetic and non-genetic host and environmental factors (1). In the last
category, chemical exposures, including drug treatment, exposure to
occupational and industrial chemicals or environmental pollutants, can
lead either to induction or inhibition of drug metabolism. Drug-drug
interactions, based on induction and inhibition of drug metabolism, are
among the most important factors complicating drug therapy and cau-
sing adverse reactions.
Induction is defined as the increase in the amount and activity of a
drug metabolising enzyme, which is a long-term (hours and days) con-
sequence of a chemical exposure (2-3). Inhibition of drug metabolism in
general may mean either an acute decrease of metabolism of a particular
substrate by another simultaneously present chemical or a time-dependent
decrease in the amount of a drug-metabolising enzyme by several factors,
such as a chemical injury or a disease process (2,4). In this review, we
will deal only with inhibition at the level of enzymes.
The cytochromes P-450 (CYP) are a superfamily of heme-thiolate
enzymes, some of which play major roles in the metabolism of drugs
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and other xenobiotics, although endogenous compounds can also be
their substrates (5,6). In humans and other mammalian species, CYP1,
CYP2 and CYP3 families are primarily associated with the Phase 1
metabolism of exogenous compounds. Over 90% of all drug metabo-
lism in man is P-450-mediated (5-9).
3. PREREQUISITES TO STUDY INDUCTION AND
INHIBITION OF CYP ENZYMES
Previously, the study of induction and inhibition of drug metabo-
lism was largely empirical and phenomenological and prediction be-
yond the compounds under actual study was very difficult, if possible
at all. During the last decade or so, however, and particularly as a con-
sequence of the detailed knowledge obtained about CYP enzymes and
their regulation by endogenous and exogenous chemicals, both induc-
tion and inhibition can be understood on a detailed mechanistic basis
and predictability of pharmacological and toxicological consequences
has become possible and even a highly desirable part of early drug de-
velopment.
As to clinical consequences of induction and inhibition, the nature of
the metabolites produced by induced or inhibited enzymes determine the
outcome. If the reaction to be studied leads to inactive product(s), in-
duction results in attenuation and inhibition results in exaggeration of the
effects of a drug. If the product is active, either pharmacologically or to-
xicologically, the reverse outcome is observed.
To be able to study induction and inhibition of CYP enzymes, there is
a need of well-characterized «selective» or «diagnostic» substrates for each
enzyme. A list of substrates which are claimed to be useful as in vitro (and
sometimes as in vivo) probe drugs for various purposes is given in Table 1.
In this table, also some information on CYP selectivity has been indicated,
although here we do not try to give more detailed and quantitative infor-
mation about this important characteristic of any model drug (2,8,9). It is of
considerable importance to analyse in a detailed and quantitative manner the
applicability and usefulness of the various proposed model drugs. Further
information on CYP substrates (and inducers and inhibitors) can be found
in several earlier and recent reviews (5,6, 11-16).
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4. INDUCTION OF CYP ENZYMES
Classically, the definition of induction is the de novo synthesis of new
enzyme molecules as a result of an increased transcription of the respec-
tive gene after an appropriate stimulus. However, in drug metabolism re-
search the term induction has been used as a generic term, describing an
increase in the amount and/or activity of a drug metabolising enzyme as
a result of an exposure to an «inducing chemical», whatever the underl-
ying mechanism. In the usual sense of induction, there is a certain lag pe-
riod before an increase in enzyme activity can be observed. This lag pe-
riod is due to the fact that it takes time to increase the amount of enzyme
molecules, either as a result of increased transcription and translation or
as result of the stabilisation of an enzyme by a substrate, which leads to
a new steady-state level between synthesis and degradation.
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TABLE 1
Compounds and reactions claimed to demonstrate a high degree of human
CYP selectivity (for CYP nomenclature, see 10; for substrates, see 5-7;
for selectivity, see 8-9)
Enzyme(s) Preferred substrate and reaction Selectivity and other remarks
CYP1A2 phenacetin O-deethylation selective
ethoxyresorufin O-deethylation selective (extrahepatic CYP1A1)
CYP2A6 coumarin 7-hydroxylation selective (all other CYPs studied 
negative)
CYP2B6 bupropion hydroxylation selective
CYP2C8 taxol hydroxylation selective
CYP2C9 tolbutamide methylhydroxylation fairly selective (other CYP2Cs) 
diclofenac hydroxylation selective
S-warfarin 7-hydroxylation selective
CYP2C19 S-mephenytoin 4-hydroxylation selective
omeprazole sulphoxidation selective
N-demethylation by CYP3A4
CYP2D6 debrisoquine 4-hydroxylation selective
dextromethorpan O-deethylation selective
N-demethylation by CYP3A4
bufuralol 1’-hydroxylation selective
CYP2E1 chlorzoxazone 6-hydroxylation selective (also by CYP1A1)
aniline 4-hydroxylation selective
CYP3A4 testosterone (steroid) 6ß-hydroxylation selective (CYP3A5)
midazolam 1-hydroxylation selective (CYP3A5)
nifedipine dehydrogenation selective (CYP3A5)
CYP3A5 as CYP3A4 substrates no selective substrate known
The basic assumption is usually that induction leads to an increased
amount of an existing enzyme (or enzymes) and not to a qualitatively dif-
ferent enzyme. This means that in the quantitative analysis the only chan-
ging measure is Vmax. Obviously, when more than one enzyme is indu-
ced, calculations will become more complicated, but still there are no
«new» enzymes present. The overall effect in vivo will still depend on
the affinities and rates of metabolism of various enzymes participating in
the metabolism of a compound under study.
An increase in enzyme activity, due to activation, is not usually in-
cluded under the term induction, although the functional outcome is simi-
lar. Some examples include the effect of alpha-naphthoflavone and a num-
ber of other substrates on the activity of CYP3A4-catalyzed reactions, due
to the peculiar substrate binding site and cooperative interactions of
CYP3A4 enzyme (17) and a rapid enhancement of antipyrine elimination
by heme arginate in porphyric patients (18), probably is due to the resto-
ration of holoenzyme by heme in the presence of intact apoenzyme.
As potential consequences of enzyme induction for drugs that are ac-
tive in their parent form, induction may increase the drug’s elimination
and decrease its pharmacological effect. For prodrugs, compounds that
require metabolic activation and whose effects are produced by the acti-
ve metabolites, enhanced pharmacodynamic effects may be expected. The
toxicological implications of enzyme induction have been discussed by
Park et al. (19).
Advances in molecular and cell biology during the past decade or so
have helped to elucidate the major mechanisms by which drugs and xeno-
biotics induce the expression of CYP genes. This occurs mainly via recep-
tor proteins that upon inducer binding are transformed into transcriptionally
active DNA-binding forms. These active receptors then bind to their DNA
response elements present in the regulatory region of the CYP genes and
greatly speed up the production of CYP mRNA, up to 50-fold or more (20).
In few instances, there are alternative mechanisms for CYP induction. The
best-characterized example is the induction of CYP2E1 by ethanol and
other small solvent molecules which appears to involve stabilization of
CYP2E1 protein through binding of the inducer to the CYP2E1 active site
(21). The role of other regulatory mechanisms, including those involving
the 3’-areas of mRNA molecules, have been presented recently (22).
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4.1. Spectrum of induction
Based on mostly animal experiments, inducers have been categorised
into several classes (Table 2), which can be characterised mainly on the
basis of the spectrum of enzymes induced and the potency of induction.
This table gives only a qualitative view of the spectrum of induction and
in the following paragraphs more background is given on mechanistic de-
tails and quantitative aspects of induction in man or human-derived
systems.
Several individual agents that induce CYP enzymes have been iden-
tified in man, and the list of drugs whose pharmacokinetics and pharma-
codynamics are affected by induction is rather long. For comprehensive
updates on such drugs the reader is referred to recent relevant reviews,
in which most original references of the subsequent chapters can be found
(5,6,21,23,24).
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TABLE 2
Traditional classification of inducers of drug-metabolising enzymes. This
classification is based mainly on animal studies, and the types of induction
are not as clear-cut in humans. (For reviews, see ref. 3,23-24)
Class Prototype inducer Principal enzymes (also non-CYP)
affected
PAH-type 2,3,7,8-Tetrachlorodibenzo-
p-dioxin CYP1A, UGT1A, GSTM
Omeprazole-type Proton pump inhibitors CYP1A2
Ethanol-type Ethanol CYP2E1
Rifampicin-type Rifampicin CYP3A
Phenobarbital-type Phenobarbital CYP1A, CYP2A, CYP2B,
CYP3A, UGT, GST
Glucocorticoid-type Dexamethasone CYP3A
Peroxisome proliferator-type Clofibrate CYP4
Abbreviations: UGT, UDP-glucuronosyltransferase; GST, glutathione transferase.
4.1.1. Cigarette smoking and PAH-like inducers
Cigarette smoking (the inducing effects of cigarette smoking is attri-
buted to the polycyclic aromatic hydrocarbon (PAH) class of compounds)
induces the metabolism of substances, which are metabolised by CYP1A
forms. These include theophylline, caffeine, antipyrine, tacrine, melato-
nin, imipramine, paracetamol (acetaminophen), and phenacetin (6). The
metabolism of these drugs is mediated predominantly by CYP1A2, one
of the relatively liver-specific CYP enzymes. CYP1A1 is mainly an ex-
trahepatic enzyme. It is highly induced in the lung, mammary gland,
lymphocytes, and placenta by PAHs and cigarette smoke (25).
The regulatory mechanisms of CYP1A induction have been thoroughly
elucidated (26,28,30). CYP1A inducers interact with the so-called Ah (Aryl
hydrocarbon) receptor, which upon ligand binding is activated and translo-
cated to the nucleus as a complex which includes also the ARNT (aryl
hydrocarbon nuclear translocator) protein. The complex binds to specific
regions in the regulatory areas of the CYP1A genes, the Ah-receptor regu-
latory elements (AhRE), also known as xenobiotic or drug responsive ele-
ments. This interaction leads to increased transcription of the CYP1A ge-
nes and the de novo production of CYP1A protein. Increased amounts of
CYP1A enzymes may have two different types of consequences: increased
toxicity due to more efficient activation of toxicants and procarcinogens
that are substrates of these enzymes (toxic response), or decreased toxicity
as a result of enhanced inactivation reactions (adaptive response) (28).
The regulation of CYP1A2 is not as well characterised as that of
CYP1A1. It is inducible by smoking, charbroiled food, cruciferous ve-
getables, omeprazole and even vigorous exercise (31,32). Although the
CYP1A-inducing capacity of omeprazole and other proton pump inhibi-
tors in the human liver and alimentary tract has been clearly demonstra-
ted, the mechanism is still somewhat unclear. However, the Ah receptor
is involved in the induction mechanism by omeprazole. It is of interest
that the inducing effect is strictly species specific, since the CYP1A1 gene
is activated in human but not in mouse hepatocytes. The overall ome-
prazole-dependent increases in CYP1A activities in the liver and gut in
vivo are rather low (usually less than two-fold) and high doses and/or pro-
longed treatments are needed to produce the inducing effect. Taken to-
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gether, the evidence suggests that the induction caused by omeprazole is
unlikely to have practical consequences (3).
4.1.2. Ethanol
Ethanol induces liver drug metabolism in humans as measured by
both in vivo and in vitro parameters. The most important CYP enzymes
induced by ethanol is CYP2E1, which serves as a mediator of the indu-
cible oxidation of ethanol and a wide variety of toxic chemicals, inclu-
ding several procarcinogens (6). Numerous agents are capable of CYP2E1
induction in the rat, but only a few, including isoniazid, appear to be an
inducer in humans (21). Isoniazid is also an inhibitor of the CYP2E1
enzyme and therefore the outcome of exposure is dependent on the spe-
cific regimen of isoniazid administration.
There is still some controversy as to whether the induction of CYP2E1
by ethanol and other substances and conditions (diabetes, ketonemia, fas-
ting etc) is transcriptional, post-transcriptional, translational or post-trans-
lational. It is probable that different mechanisms are operative in diffe-
rent situations and conditions (21).
4.1.3. Phenobarbital and other antiepileptic drugs
Phenobarbital is the archetypal inducer of drug metabolism (33). Phe-
nobarbital has long been known to be a strong and broad-spectrum in vivo
inducer of drug metabolism. As an example of the potency of induction,
the dose of warfarin required for the anticoagulant effect can be increa-
sed up to ten-fold during phenobarbital treatment. Also other antiepilep-
tic drugs, especially phenytoin and carbamazepine, have been shown to
induce drug metabolism in humans. Antiepileptics are broad-spectrum in-
ducers, enhancing the metabolism of numerous drugs, including warfa-
rin, cyclosporin A, theophylline, oral contraceptives and their own meta-
bolism, leading to autoinduction (34).
In rodents, phenobarbital induces CYP forms in several subfamilies, in-
cluding CYP1A, CYP2A, CYP2B and CYP3A, the members in the CYP2B
subfamily reacting most sensitively (33). Several lines of evidence suggest
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that in humans, the CYP3A forms are the ones most affected by phenobar-
bital and other antiepileptic drugs, but also other CYP enzymes, CYP2B6,
members of the CYP2C subfamily (CYP2C8, CYP2C9 and CYP2C19) and
CYP2A6, respond to antiepileptic drug treatment (26,29,33).
The mechanism mediating phenobarbital is characterised in a great
detail during the last few years (26). A specific nuclear receptor termed
CAR (constitutive androstane or constitutively active receptor) mediates
CYP2B induction by phenobarbital and other similar compounds. Endo-
genous ligands for CAR are androstanes, for example androstanol, and it
is peculiar to this receptor, that endogenous ligands are inhibitory. In the
presence of phenobarbital, however, the constitutively active receptor is
released and receptor activity is thereby de-repressed (26).
4.1.4. Rifampicin and corticosteroids
Rifampicin induces CYP3A enzymes in the liver, although weak in-
duction of other CYP enzymes, including CYP2A6, CYP2C and
CYP2B6, have also been noticed. Consequently, rifampicin accelerates
the elimination of a large number of substances, although most of them
are substrates for CYP3A4, such as midazolam, quinidine, cyclosporine
A and many steroids (6). CYP3A enzymes are also present in the gut, and
rifampicin is able to induce the gut enzymes, leading to an enhanced first
pass effect for CYP3A4 substrates.
It is now known that rifampicin induces CYP3A4 and some other
enzymes by binding to a nuclear receptor called PXR (pregnane X re-
ceptor) (27,29). PXR dimerizes with another nuclear receptor called RXR
(retinoid X receptor) and this dimer binds to an appropriate binding ele-
ment in the 5’-region of the gene to be induced. Endogenous ligands for
the PXR receptor include pregnenolone derivatives and a number of other
steroids. Also several glucocorticoids, dexamethasone as a prime exam-
ple, also bind to PXR, causing CYP3A4 induction.
4.1.5. Peroxisome proliferators
It is well established that several agents that cause peroxisome proli-
feration in the liver, such as clofibrate and nafenopin, are potent hepato-
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carcinogens and inducers of the CYP4A subfamily forms in rodents (35).
A specific nuclear receptor called PPAR (peroxisome prolifarator activa-
ted receptor) binds peroxisome proliferators and certain polyunsdaturated
long-chain fatty acids as endogenous ligands, forms a heterodimer with
the RXR, and causes the activation of CYP4A genes (36), as other nu-
clear receptors.
Humans seem resistant to the peroxisome proliferating effects pro-
duced by this class of compounds, and they are not considered to pose a
hepatocarcinogenic hazard to humans. Due to the very low abundance of
CYP4A protein in the human liver and paucity of relevant drug substra-
tes, its role in the overall pharmacokinetics of commonly used drugs must
be considered as negligible.
5. INHIBITION: MECHANISMS AND QUANTITATION
The in-depth treatment and formal derivation of equations to charac-
terise various modes of inhibition can be found in appropriate textbooks
and handbooks. A good introduction to the basic phenomena of inhibi-
tion of drug metabolism is a book chapter of Boobis (4). Further readings
on various basic and applied aspects of inhibition of drug metabolism can
be found in several fairly recent reviews (37-43). The present treatment
of the subject is restricted to CYP enzymes.
5.1. Inhibitory spectrum
In terms of understanding and predicting the outcome of inhibitory
interactions, selectivity of a particular inhibitor towards CYP enzymes is
of utmost importance. Many substances are relatively non-specific and
even those claimed to be enzyme-specific usually have affinity to other
enzymes, although this occurs only at higher concentrations (see table 3).
One good example is cimetidine, a well-known inhibitor of P-450-linked
reactions and one of the first inhibitors of drug metabolism to attract a
lot of attention in clinical drug therapy (44). It has been shown that ci-
metidine interacts with at least human hepatic CYP1A, 2C, 2D, 2E and
3A forms, but with widely variable affinities (43).
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5.2. Inhibitory potency in vitro
The most important single measure for inhibitory potency of a given
compound is the Ki value, or inhibition constant, which expresses an af-
finity of a compound to an enzyme. It should be stressed here, that a Ki
value is characteristic for each particular inhibitor and enzyme, and it is
not dependent on any particular substrate used for the quantitation of an
enzyme. With respect to human hepatic CYP enzymes, this value can be
easily measured with standard in vitro approaches, in which various con-
centrations of a substance are incubated with human liver microsomes
and an inhibition of a CYP-specific model reaction is quantitated. A subs-
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TABLE 3
Induction of major human CYP enzymes by various inducers and their
regulatory factors. (For reviews of different induction mechanism,
see ref 26-30)
Gene Typical inducers Major regulatorfamily activated by inducer Comments
CYP1A Polycyclic aromatic Ah receptor Modulated by protein kinases
hydrocarbons, cigarette Omeprazole mechanism still
smoking, omeprazole unclear
CYP2A Rifampicin, barbiturates Unknown Modulated by cAMP
(CAR, PXR ?) mRNA stabilization
CYP2B Barbiturates, antimycotics, CAR, PXR Modulated by glucocorticoids 
phenothiazines, etc. and protein kinases
Nuclear translocation
Species differences
CYP2C Barbiturates, antimycotics, CAR, PXR
phenothiazines, etc.
CYP2E Ethanol, isoniazid, Stabilization of Multiple mechanisms in rodents
acetone CYP2E1
CYP3A Rifampicin, barbiturates, PXR, CAR Species differences
antimycotics, pheno- PXR and CAR share ligands and
thiazines, etc. target genes
CYP4A Fibrates PPARa low PPAR a levels in humans
tance may have affinity for an enzyme without being metabolised by the
same enzyme (e.g. quinidine for CYP2D6) or it may be an alternative
substrate of the enzyme and serve as an inhibitor on this basis. In both
cases the Ki value is derived from an in vitro experiment, but for an al-
ternative substrate, a Ki value should be the same as its Km value.
It may be worth of stressing here that assay conditions such as pro-
tein concentration, buffer, ions, pH and so on, may critically affect the
inhibitory potency of the compound (45,46) and should be thoroughly in-
vestigated.
5.3. Inhibition of clearance
For any substrate, the ratio Vmax/Km is a measure of intrinsic clearan-
ce, which relates to the efficacy of an enzyme to metabolise a substrate.
Usually, in clinical usage, drug concentrations are far below their Km va-
lues, and in this situation it can be demonstrated that the intrinsic clea-
rance is decreased dependent on the ratio between the concentration of
an inhibitor to its Ki value [I]/Ki. This statement is true for whatever the
mechanism of inhibition may be. Assuming competitive inhibition and
the substrate concentration far below its Km value (i.e. [S]<< Km ), the
percentage inhibition can be simply calculated according to the equation
I/(I+Ki) x 100. It has to be stressed that the number achieved is a very
crude “first guess” and depends on a number of other factors which have
been discussed in, for example, Boobis (4) and Pelkonen et al (2).
However, when substrate concentrations approach and exceed Km va-
lues, the mechanism of inhibition becomes important. In a competitive
mode of inhibition, increasing substrate concentration abolishes inhibi-
tion because the inhibitor is increasingly removed from the active site of
an enzyme. In this case, the denominator of the above mentioned simple
equation should contain the term (1-[S]/ Km ); the higher the substrate
concentration [S], the lower the percentage inhibition. However, in a non-
competitive mode of inhibition, a certain proportion of an enzyme, which
is determined by the ratio [I]/Ki, is «inactivated» for a more prolonged
period of time, being unavailable for catalysis, and the inhibition cannot
be abolished by increasing the substrate concentration.
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5.4. Mechanism based inhibition
For the CYP enzymes, the inhibitory species may not be a the subs-
trate itself, but a metabolite, which is then complexed or covalently bound
to a metabolising enzyme itself («suicide inhibition») or to other enzy-
mes nearby. The consequence is a removal of a variable proportion of an
enzyme from active catalysis, i.e. a non-competitive mode of inhibition.
However, the detection of mechanism-based inhibition requires specific
incubation conditions. A preincubation of liver microsomes in the pre-
sence of an inhibitor under the metabolising conditions is necessary, be-
cause the presence of a substrate might competitively inhibit the meta-
bolism of a mechanism-based inhibitor. A specific case of mechanism
based inhibition is the situation in which an enzyme is inactivated very
slowly during in vivo conditions. In this case it is difficult to reveal in-
hibition in in vitro experiments.
5.5. Concentration of the inhibitor
Whatever the exact value of Ki is, it does not directly tell us inhibi-
tion will be observed during the in vivo use of a compound. The critical
factor in the term [I]/Ki is the concentration of an inhibitor, which ide-
ally means the concentration at the active site or a modulatory site. Ob-
viously, this particular concentration is not known and surrogate values
are usually used, such as total or free concentration in the plasma. Most
authors think that the unbound, (i.e. free concentration) is the most ap-
propriate to use, because it is only free drug that is able to transfer to he-
patocytes and to the vicinity of CYP enzymes. However, it is conceiva-
ble —and for some drugs even shown— that many lipid-soluble drugs
are concentrated in hepatocytes and consequently the actual concentra-
tion in the liver far exceeds that in plasma. Even the measurement of the
partition between liver and plasma does not necessarily indicate the avai-
lable portion of a drug to an enzyme, because a drug may be very tightly
bound inside hepatocytes and may not be available to the active site of
the enzyme. A detailed and extensive treatment of modelling and predic-
ting interactions of drug metabolism, including factors affecting partition
between liver and plasma, can be found in Leemann and Dayer (38).
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5.6. Clinical significance of an interaction
Affinity and CYP selectivity can be studied in vitro and thus a potential of
a drug to cause interactions can be revealed. However, this does not yet mean
that the compound would cause clinically significant interactions. For such
interactions to ocuur, two prerequisites have to be fulfilled: 1) The concentra-
tion of the drug in clinical situation should be high enough, so that inhibition
would be manifested in vivo. 2) The therapeutic index of the drug should be
narrow, such that a change caused by an interacting drug would cause side ef-
fects. The clinical significance of a drug interaction involves also a judgemen-
tal component, which in most cases is rather large. The judgmental compo-
nents involve the severity of potential harm to the patient, assessment of
decreased therapeutic outcome and so on. This makes it difficult to say une-
quivocally whether an interaction is «clinically significant». Semiquantitative
classifications have been constructed, such as that of Preskorn (47) using the
terms «Substantial», «Moderate», «Mild», «Unlikely», «Not clinically signifi-
cant». However, in the end clinical assessment and judgment is the final arbi-
ter as to the clinical and therapeutic significance of an interaction and this as-
sessment may be difficult to put into exact numbers and may cause
disagreement even between experts. However, a sort of yardstick to aid in the
assessment of clinical significance of interactions is to keep in mind a list of
interactions that have been demonstrated to be clinically significant (Table 4).
6. MEASURING INDUCTION AND INHIBITION IN DRUG
DISCOVERY AND DEVELOPMENT
“Flaws” in metabolic and pharmacokinetic behaviour of a new chemical
entity have been some of the major reasons for the termination of development
and also withdrawal from the clinical use. Because drug development is hu-
gely expensive, appropriate metabolic and kinetic characteristics of molecules
and candidates should be screened as early as possible during the process. Ob-
viously, before the first introduction of a new chemical entity (NCE) into a li-
ving human, only in vitro systems or animals could be used for screening pur-
poses. Due to extensive interspecies differences (see Pasanen’s chapter), use of
animal in vitro or in vivo systems has severe restrictions and human-derived
systems are clearly preferable. Below, a short outline of induction and inhibi-
tion screening systems available early in drug development is described.
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6.1. CYP specificity of metabolism and interactions of a NCE
A prerequisite for rational study and prediction of metabolic interactions
is the knowledge of CYP specificity of metabolism or affinity of a NCE.
Currently there are a number of approaches available to study of the role of
known CYPs in the metabolism and affinity of any xenobiotic.
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TABLE 4
A compilation of inhibitors, which have claimed to demonstrate some
CYP enzyme selectivity. (For original references, see ref 2 and 6)
CYP Inhibitor Mechanism of inhibition Selectivity Effect
in vivo
1A2 Furafylline mechanism-based very selective +++
Fluvoxamine competitive also 2C19, 3A5 +++
2A6 Methoxalen mechanism-based also 1A2, 2E1 +
Trancylcypromine competitive reasonably selective +
2B6 Ticlopidine partially mechanism-based reasonably selective +
Thiotepa competitive very selective ?
2C8 No known
2C9 Sulfaphenazole competitive very selective +++
Tienilic acid mechanism-based ? ++
2C19 Fluvoxamine competitive also 1A2, 3A4 +
2D6 Quinidine competitive very selective +++
2E1 Diethyldithiocarbamate mechanism-based also 2A6 ++
4-Methylpyrazole competitive also 2A6 ++
Disulfiram mechanism-based also 2A6 ++
3A4 Troleandomycin metabolic intermediate complex selective +++
Erythromycin metabolic intermediate complex selective ++
Ketoconazole competitive reasonably selective +++
Gestodene mechanism-based ? +?
If the principal metabolic routes of a NCE have been elucidated and
a method is available for their quantitation in in vitro incubations, it is
possible to employ «diagnostic» inhibitors (Table 5) and look which of
them, and at which concentrations, inhibit metabolic routes. It is also pos-
sible to use enzyme-specific antibodies and to test which metabolic rou-
tes are inhibited and to what extent by a particular anti-CYP antibody. In
a panel of human liver microsomes it is possible to correlate the meta-
bolism of a compound under study with the activities of CYP-specific
model reactions and thus get an idea about enzyme(s) catalysing the re-
action. Practically all major CYP enzymes have been expressed in va-
rious host cells, such as bacteria, yeast and mammalian cells, and it is re-
latively straightforward to study either the metabolism of, or inhibition
by, a compound under study in a cell system expressing a particular CYP
enzyme. More extensive coverage of these approaches can be found in
recent reviews (48-51).
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TABLE 5
Examples of drugs that have considered to cause clinically significant
drug-drug-interactions
Inhibitor(s) Target CYP Drugs affected Remarks
furafylline CYP1A2 caffeine, theophylline furafylline 
withdrawn from 
development
fluvoxamine CYP1A2, 2C19 CYP1A2 substrates warnings in PDRs
Sulfaphenazole, other CYP2C9 warfarin warnings in PDRs
CYP2C9 inhibitors
Quinidine CYP2D6 all CYP2D6 substrates warnings in PDRs
(antidepressants, 
antipsychotics etc)
Azole antimycotics CYP3A4, most statins, calcium warnings in PDRs, 
(ketoconazole, many others channel blockers, 
itraconazole) cyclosporin A etc
Mibefradil withdrawn
Terfenadine, withdrawn
Astemizole
It is possible to make a number of predictions on the basis of the
known characteristics of each CYP enzyme and on the basis of the known
CYP-specificity of the metabolism of a NCE. For example, if it is known
that the CYP3A4 enzyme participates in the metabolism or interactions
of a particular substance (as is often the case), it is possible to identify
some matters of concern on the basis of what is generally known about
CYP3A4. The following list of predictions is from the review articles of
Watkins (52) and Wilkinson (53).
a) CYP3A4 is induced by rifampicin, antiepileptics, dexamethasone
etc and consequently, the elimination of a NCE might be enhanced in si-
tuations involving administration of these drugs. b) CYP3A4 levels are
inhibited by ketoconazole, itraconazole and a large number of other com-
pounds, as well as by grapefruit juice. The metabolism of a NCE might
be inhibited by these substances. c) CYP3A4 is activated by several fla-
vones and endogenous steroids. The flavones, which are constituents of
food, may enhance the metabolism of substrates of CYP3A4. d) CYP3A4
is very variable between individuals. Also, the elimination of a NCE may
be variable. e) CYP3A4 is present in intestinal epithelium. This fact may
lead to a first-pass effect, i.e. reduced bioavailability of a NCE. f)
CYP3A4 displays an age-related reduction in activity. The elimination of
a NCE may show the same phenomenon. g) CYP3A4 activity is decrea-
sed in liver cirrhosis. The elimination of a NCE is expected to be decre-
ased in severe liver disease. However, it has to be stressed that the sig-
nificance of the above predictions are highly affected by principally
quantitative considerations. For example: what is the proportion of me-
tabolic clearance through the specific enzyme? It is clear that a 90 % por-
tion of metabolic clearance through, say, CYP3A4 means a very high li-
kelihood of predictions to be fullfilled than in the case, where only 20 %
of metabolic clearance is through CYP3A4.
6.2. Assay systems for induction
Induction of human CYP enzymes is difficult to study because there
are no human liver cell lines that express the full complement of CYP
enzymes nor reproduce the induction observed in vivo, apart from the Ah
receptor-mediated induction of CYP1A1 gene. Problems in tissue availa-
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bility, interindividual differences, reproducibility, and ethical issues pre-
clude the efficient large-scale use of human primary hepatocytes for in-
duction screening (20, 57). Therefore, there is an increasing interest in
the development of mechanism-based test systems for CYP induction, ba-
sed on the characterized nuclear receptors AHR, CAR, PXR, and
PPAR((29). The interaction of inducers with the particular receptor is ex-
ploited in an attempt to predict CYP induction at least in the following
ways:
1) Direct binding assays rely on the ability of the putative inducer
to displace a radioactively labelled receptor ligand.
2) Indirect binding assays measure the association of fluorescently
labeled coactivator peptide with the inducer-bound receptor. The
receptor can also be linked to another fluorophore to utilise the
fluorescence resonance energy transfer (FRET) phenomenon in
the assay.
3) Cell-based reporter gene assays measure the ability of inducer-
bound receptor to interact with endogenous cellular coactivators
after binding to its DNA response element that drives the ex-
pression of an easily assayable reporter gene such as luciferase
or CAT enzyme.
6.3. Assay systems for inhibition
The most widely used in vitro system to study CYP inhibition is to me-
asure affinities of a NCE for CYPs in CYP-selective model substrate as-
says (2,4,56,58). From the therapeutic point of view, it is important to know
which drug-metabolising enzymes the substance under development has af-
finity to. The effects of a NCE on metabolite formation in the selected mo-
del system, usually human liver microsomes, are evaluated by incubating
the substrate and the studied compound with the enzymes and observing
the potential inhibition of metabolite formation in incubations with the stu-
died compound. Testing the effects of an NCE on CYP-specific model ac-
tivities and the effects of CYP-specific reference inhibitors on the metabo-
lism of an NCE in human liver microsomes in vitro gives information about
the affinity of an NCE for CYP enzymes. By comparing the effects of an
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NCE on the CYP specific-activities with the respective effects of diagnos-
tic inhibitors, a tentative prediction of the in vivo situation can be made.
This approach also permits in vivo predictions about the behaviour of a
NCE in man (metabolic pathways, intrinsic clearance, etc.), which helps to
design in vivo studies for revealing possible interactions.
After the above studies, it is possible to plan further preclinical, mo-
lecular, toxicological and clinicopharmacological studies, with focussed
consideration of those CYP enzymes which are of importance for the me-
tabolism and kinetics of an NCE.
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FIGURE 1. Induction of drug metabolism by CYP enzymes are predominantly 
receptor-mediated.
The xenobiotic compounds (X, Y) can increase their own metabolism to more hydrophilic
metabolites (XO, YO) through binding to any of the ligand-activated nuclear receptors (CAR,
PXR, PPAR) or the aryl hydrocarbon receptor (AhR). The activation of these receptors by X,
Y then results in increased CYP gene transcription. CYP2E1 inducers usually stabilise the
CYP2E1 protein without any gene activation (modified from Pelkonen et al 2002, ref. 3).
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TABLE 6
Probe drugs/substances claimed to be useful in vivo in man
(modified from Pelkonen et al 2002, ref. 3)
CYP Probe drug Methods Remarks2
available1
1A2 Caffeine (N-demethylations) pm/u Wide recreational use
Furafylline adm po W; selective
Fluvoxamine (inhibitor) adm po Inhibits also CYP2C19 and CYP3A4
2A6 Coumarin (7-hydroxylation) pm/u,(pm/b) W; kinetically unsuitable
Tranylcypromine (inhibitor) adm po C; not validated in vivo
2B6 Bupropion (hydroxylation) pm/b, pm/u C; not validated
2C9 Tolbutamide (methylhydroxylation) pm/b, pm/u W; well validated; safety?
Diclophenac (4-hydroxylation) pm/u, pm/b C; Under validation
Sulfaphenazole (inhibitor) adm po C; well validated
2C19 Mephenytoin (1-hydroxylation) pm/u W; extensively used; safety?
2D6 Debrisoquine (4-hydroxylation) pm/u W; extensively used; safety?
Dextromethorphan (O-demethylation) pm/u C; well validated
Quinidine (inhibitor) adm po C; well validated
2E1 Chlorzoxazone (6-hydroxylation) pm/b, pm/u C; well validated
Disulfiram (inhibitor) adm po C; inhibits also CYP2A6
3A4 Midazolam (1’-hydroxylation) pm/b, pm/u C; well validated
Ketoconazole (inhibitor) adm po C; peroral use not common
Itraconazole (inhibitor) adm po C; well validated; selective
1 symbols: p, parent drug; m, metabolite(s); b, blood (plasma, serum); u, urine; s, saliva; (r), radioactive label; ex, exha-
led air; adm iv, administered intravenously; adm po, administered perorally.
2 C, clinically used drug; W, withdrawn from the market or not been used as a pharmaceutical.
3 for references concerning each probe drug, see section IIA in Rendic (6). A review of Streetman et al (59) presents a
critical appraisal of CYP substrate probes.
In clinical and clinicopharmacological studies, it is important to find sui-
table model substances, which can be used in in vivo conditions. In Table
6, some substrates and inhibitors are listed the in vivo usefulness in mind.
It is clear that the in vivo use places very thorough requirements for drugs
to be used, because safety and ethical aspects are of utmost importance. It
is also quite clear that only very few inducers can be used in clinicophar-
macological studies —probably rifampicin is the only example— when the
use is not associated with the treatment of the disease. One of the approa-
ches to overcome these problems could be the use of microdosing.
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